Arabic Arabic English English French French German German
dark

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

UCB announced that the U.S. Food and Drug Administration has approved an expanded indication for BRIVIACT CV tablets, oral solution, and injection to treat partial-onset seizures in patients as young as one month of age. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

XPhyto Launches First Commercial Biosensor for Oral Disease

Next Post

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Related Posts
Total
0
Share